Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.

DUBLIN, May 15, 2023 /PRNewswire/ -- The "2023 Bone & Joint Health - Douyin, China E-commerce Market Data Subscription" database has been added to ResearchAndMarkets.com's offering. This database subscription gives you all the information you need on the market for bone and joint supplements in the Chinese market, as measured on the Douyin platform. The data subscription service provides you with valuable information on consumer behavior and preferences, top-selling product categories and brands, pricing strategies, trends, and more. With The data, you can make informed decisions about market entry, product development, and marketing optimization that can help you succeed in this highly competitive industry. Whether you're a startup looking to break into the market or an established business seeking to expand your reach and grow your profits, our China ecommerce data subscription for health supplements is a powerful tool that can help you stay ahead of the curve. The analyst acquires product level data for each platform on a weekly basis, including sales volume, price, promotion, brand, store, link and other available information, and agregate it by month. All the data is carefully processed, classified and tagged with a selection of over 4000 brands, functions, ingredients, target user, formats, packaging, and country of origin labels. You will be able to access the data through Qlik Sense, a powerful web-tool that gives you access to the data to explore trends and market drivers, and deep dive into brands, companies, stores, segments and product details. This is facilitated by four select dashboards which include Segments, Executive Summary, Performance Drivers and Category Details. All dashboards can be filtered through the main filters or based on your search and selections across dashboards. Segments dashboard: Easily see the performance over time of your category and sub-categories and explore ingredients, function, format and other trends. Executive Summary dashboard: Provides brand performance at a glance. Always have key metrics at your fingertips and understand how the market and competitors are changing. Performance Drivers dashboard: Your cheat-sheet for all things brands. Expands upon the Executive Summary with more details. Understand who wins and who loses and what pricing strategy your competitors are driving. Category Detail dashboard: Explore parent companies, brands, stores and individual items in detail. Product level information include product name, store, price, volume, value, platform link, etc. Data reporting in other forms, such as monthly Excels, dedicated reports, API access are available as upgrades upon request. This data subscription product provides monthly data releases throughout 2023, with the previous months data published by the 20th the following month. There is the option to continue the service the following years while retaining present data. In addition, the data includes six month of history - July 2022 to December 2022. Customers also have the option to upgrade to include more history. Key Topics Covered: Monthly data for the respective category and subcategory (if available): Product Name Shop Name Price Sales Volume Sales Value Platform URL Tags - Brand Function Ingredient Country of Origin Format Package Target User Web portal to access data with following dashboards: Segments Executive Summary Performance Drivers Category Detail A selection of companies mentioned includes Reckitt By-Health Blackmores Usa Reaps Nutrition Health Products Ins Allnature Pharm Jemllo H&H Hpgc Nestle Ezz Conba Jbx Pty Ltd Tongren Tang Bechi Curarti Health Spring Isdg Haleon Nature's Care Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Good Health Beijing Guangbo Huizhi Technology Development Co. Ltd. Webber Naturals Gnc Beijing Kangyuan Pharmaceutical Co. Ltd. Renhe Group Co. Ltd. Queisser Pharma Robinson Pharma Xiangyun Yansong Guangdong Weishiya Health Technology Co. Ltd. Synext Xiuzheng Pharmaceutical Group Co. Ltd. Ny-O3 Esmond Natural Hong Fu Loi Jamieson Wellness Costco Now Foods Vitalis Pharma As Xiamen Kingdomway Group Company Ziguang Technology Pipingrock Plameca Orihiro NBTy Life Extension Kuihua Shandong Zhenkang Biotechnology Co. Ltd. Sanaexpert Bai He Nutryfarm Pharmavite Warnke Joy Life Mingshi Reaps Kang Long Group Corp Naturelan for Becared One Style Japan Fairvital Aland Orthomol Fitline Wright Life Purmeo Noguchi Medical Research Institute Blue Bay Herbs of Gold Folotto Fair&Pure Sams Club Nature's Truth Beijing Aotai Health Care Products Co. Ltd. Sanderson Fine Usana Anhui Huajun Medical Ltd Vytalogy Wellness Youthit For more information about this database visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

After winning approval about six years ago, the first wave of PCSK9 inhibitors largely failed to muster the blockbuster sales analysts had predicted. Now Merck is hoping its oral option will find better success. The pharma giant unveiled on Monday what it says are the first in-human results for an oral PCSK9 inhibitor. The candidate, MK-0616, was well-tolerated in men and women with high cholesterol at doses up to 300 mg, with no deaths or serious side effects, the company said at the American Heart Association conference. In addition, the experimental drug reduced blood levels of free PCSK9 by more than 90% from baseline when administered as a single dose between 10 and 300 mg, Merck announced. In a multiple-dose study, LDL-cholesterol (also known as bad cholesterol) decreased by about 65% from baseline in patients who took MK-0616 on top of their current statin therapy for 14 days. “The initial results are encouraging; however, more clinical studies are needed to confirm these findings, given limited clinical experience with the molecule MK-0616,” lead study author Douglas Johns said in a statement. PCSK inhibitors work by blocking a liver protein that helps to destroy LDL-C receptors on the surface of cells. Those receptors are responsible for taking cholesterol out of the blood stream. Therefore, more active receptors means less bad cholesterol. Sanofi and Regeneron’s Praluent and Amgen’s Repatha were the first to secure approvals here, marking the first big cholesterol drugs since Lipitor. Analysts had predicted megablockbuster sales — but payers, weary of funding a chronic treatment for a large patient population, did everything possible to keep patients on cheap generics. That led to major price cuts, and in 2019, Sanofi lopped off its cardio division altogether. Novartis shelled out $9.7 billion for The Medicine Company’s PCSK9 drug inclisiran that same year, planning for a swift US approval. But after getting slapped with a CRL last year, the company released more post-hoc data this week at AHA in the hopes of finally getting it past the goal line. Novartis touts inclisiran (which is injected twice a year) as an easier option than Repatha and Praluent, which require dosing every two weeks or monthly, respectively. Merck, on the other hand, thinks it can skip the needles altogether. “I believe this is the first report of successful oral absorption of a synthesized cyclic peptide like MK-0616 in people,” Johns said. “We were pleased that it appeared to be consistently absorbed and concentrated in patients’ blood, and that it reduced cholesterol levels so effectively.”